FTC stated that the 'Big 3' PBM organisations collectively generated over £5.94 billion ($7.3 billion) in revenue from 2017 to 2022.

Discover how the three largest pharmacy benefit managers are rejecting biosimilars from their formularies, except for their own private-label drugs.

The lawsuit claims that three major healthcare companies were pushing up the price of insulin by 1,200 percent.

UnitedHealth, the biggest insurance company in America, is receiving backlash after an FTC report revealed that it was ...

The City of Greensboro, North Carolina, which provides public safety, emergency, and health services to over 300,000 residents and spends millions annually on insulin medications, filed a lawsuit last ...

Even as a move to regulate pharmacy benefit managers like Express Scripts gets bipartisan support in Congress, a Missouri ...

Oklahoma's attorney general has accused CVS's Caremark pharmacy benefit manager unit of under-reimbursing pharmacies for ...

Birmingham is suing drug manufacturers and health companies, alleging they worked together to establish an “insulin pricing scheme” and inflate the cost of life-saving medicine.

Sen. James Lankford has been trying to pass legislation in response to an industry he believes will leave small towns without ...